Synthesis and Anti-inflammatory Properties of 1α,25-Dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a Hypocalcemic, Stable Metabolite of 1α,25-Dihydroxy-16-ene-20-cyclopropyl-vitamin D3

被引:37
|
作者
Laverny, Gilles [1 ]
Penna, Giuseppe [1 ]
Uskokovic, Milan [2 ]
Marczak, Stanislaw [2 ]
Maehr, Hubert [2 ]
Jankowski, Pawel [2 ]
Ceailles, Caroline [3 ]
Vouros, Paul [3 ]
Smith, Brenden [4 ]
Robinson, Matthew [4 ]
Reddy, G. Satyanarayana [4 ,5 ]
Adorini, Luciano [1 ]
机构
[1] BioXell, I-20132 Milan, Italy
[2] BioXell Inc, Nutley, NJ 07110 USA
[3] Northeastern Univ, Dept Chem, Barnett Inst, Boston, MA 02115 USA
[4] Epimer LLC, Providence, RI 02906 USA
[5] Brown Univ, Dept Chem, Providence, RI 02912 USA
关键词
VITAMIN-D-RECEPTOR; 1,25-DIHYDROXYVITAMIN D-3; ANALOG; INHIBITION; GROWTH; PARENT; CELLS;
D O I
10.1021/jm801365a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
1 alpha,25(OH)(2)-16-ene-20-cyclopropyl-vitamin D-3 (13) is several fold more potent than the natural hormone 1 alpha,25-dihydroxyvitamin D-3 (1) as an anti-infilammatory agent. Here, we have further analyzed the anti-inflammatory properties of 13, confirming it as the most potent analogue tested within this family. We then determined the structures of all the natural metabolites of 13, including the 24-oxo metabolite 14, and carried out its synthesis. A comparison of 13 with 14 showed a similar induction of the primary VDR target genes CYP24A1 and CAMP and comparable anti-inflammatory properties as revealed by a similar inhibition of TNF-alpha, IL-12/23p40, IL-6, and IFN-gamma production. Interestingly, 14 displays a 3-fold lower calcemic activity in vivo compared to 13. Collectively, these findings indicate that the strong potency of 13 can be explained by the accumulation of its stable 24-oxo metabolite, which shows immunoregulatory and anti-inflammatory properties superimposable, to those exerted by 13 itself.
引用
收藏
页码:2204 / 2213
页数:10
相关论文
共 41 条
  • [11] Characterization of five 19-nor-analogs of 1α,25(OH)2-Vitamin D3 with 20-cyclopropyl-modified side-chains:: implications for ligand binding and calcemic properties
    Olivera, CJ
    Bula, CM
    Bishop, JE
    Adorini, L
    Manchand, P
    Uskokovic, MR
    Norman, AW
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5) : 99 - 106
  • [12] 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression
    Sakai, Sadaoki
    Takaishi, Hironari
    Matsuzaki, Kenichiro
    Kaneko, Hironori
    Furukawa, Mitsuru
    Miyauchi, Yoshiteru
    Shiraishi, Ayako
    Saito, Keiji
    Tanaka, Akio
    Taniguchi, Tadatsugu
    Suda, Toshio
    Miyamoto, Takeshi
    Toyama, Yoshiaki
    JOURNAL OF BONE AND MINERAL METABOLISM, 2009, 27 (06) : 643 - 652
  • [13] Double bond in the side chain of 1α,25-dihydroxy-22-ene-vitamin D3 is reduced during its metabolism:: studies in chronic myeloid leukemia (RWLeu-4) cells and rat kidney
    Rao, DS
    Balkundi, D
    Uskokovic, MR
    Tserng, KY
    Clark, JW
    Horst, RL
    Reddy, GS
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 78 (02) : 167 - 176
  • [14] Synthesis, metabolism, and biological activity of 2-[3-(tetrazolyl)propyl]-1α,25-dihydroxy-19-norvitamin D3
    Takano, Masashi
    Yasuda, Kaori
    Higuchi, Erika
    Tohyama, Eri
    Takeuchi, Akiko
    Sakaki, Toshiyuki
    Kittaka, Atsushi
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2016, 164 : 40 - 44
  • [15] Design and synthesis of 2α-(tetrazolylethyl)-1α,25-dihydroxyvitamin D3 as a high affinity ligand for vitamin D receptor
    Matsuo, Miki
    Hasegawa, Asami
    Takano, Masashi
    Saito, Hiroshi
    Kakuda, Shinji
    Takagi, Kenichiro
    Ochiai, Eiji
    Horie, Kyohei
    Takimoto-Kamimura, Midori
    Takenouchi, Kazuya
    Sawada, Daisuke
    Kittaka, Atsushi
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014, 144 : 201 - 203
  • [16] Tissue specific metabolism of 1α,25-dihydroxy-20-epi-vitamin D3 into new metabolites with significant biological activity:: Studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8)
    Siu-Caldera, ML
    Rao, DS
    Astecker, N
    Weiskopf, A
    Vouros, P
    Konno, K
    Fujishima, T
    Takayama, H
    Peleg, S
    Reddy, GS
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2001, 82 (04) : 599 - 609
  • [17] S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death
    Wu, Wei
    Zanello, Laura
    Walker, Ameae M.
    PROSTATE, 2007, 67 (14) : 1498 - 1506
  • [18] New derivatives of 1α,25-dihydroxy-19-norvitamin D3 with two substituents at C-2:: synthesis and biological activity
    Shimizu, M
    Iwasaki, Y
    Shimazaki, M
    Amano, Y
    Yamamoto, K
    Reischl, W
    Yamada, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) : 1451 - 1455
  • [19] SYNTHETIC STUDIES OF VITAMIN-D ANALOGS .9. SYNTHESIS AND DIFFERENTIATION-INDUCING ACTIVITY OF 1-ALPHA,25-DIHYDROXY-23-OXA-VITAMIN-D3, THIA-VITAMIN-D3, AND AZAVITAMIN-D3
    KUBODERA, N
    MIYAMOTO, K
    AKIYAMA, M
    MATSUMOTO, M
    MORI, T
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1991, 39 (12) : 3221 - 3224
  • [20] Synthesis and biological activities of new 1α,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain
    Shimizu, Masato
    Miyamoto, Yukiko
    Kobayashi, Emi
    Shimazaki, Mika
    Yamamoto, Keiko
    Reischl, Wolfgang
    Yamada, Sachiko
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (12) : 4277 - 4294